ORYZON Receives $1.5 million grant from Alzheimer’s Drug Discovery Foundation (ADDF)

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced todaythat the Board of Directors of the Alzheimer’s Drug Discovery Foundation (ADDF) has approved a grant of $1.5 millionto Oryzon Genomics S.A. to support theUS-arm of Oryzon’sETHERAL PhaseIIaclinical trialwith vafidemstatin Alzheimer’s disease(AD)patients.

ETHERAL (Epigenetic THERapy in ALzheimer’s Disease)is already beingconducted in 17 EuropeanhospitalsacrossUK, France and Spain. It isdesigned as a randomised, double-blind, placebo-controlled, 3-arm, 26weeks parallel-group study to evaluate the safety and tolerability of vafidemstat in patients with mild and moderate AD. The study incorporates a multiplicity of secondary endpoints measurements, including memory and behavior alterations. The study also monitors the variations of diverse CSF biomarkers including anti-inflammatory ones. The European arm of the study plansto enroll up to 125 patients, withmore than 90 patients randomized up to date.

Recently, the company got FDA’sIND approval to start the US arm of this study. This arm will involve multiple sites in the US andplansto enroll up to 30 patients, to complete a minimum of 150patients on the aggregate.

Under the terms and conditions of the grant, the ADDF has received 367,250 ordinary shares of the Company, representing 0.94% of the capital.

Vafidemstat is a neuroactive molecule which is also being exploredin other CNS and psychiatric conditions. The company recently reported first human efficacy data inreducing aggression inan open-label Phase IIa trial (REIMAGINE) in Borderline-personality Disorder (BPD) and Attention Deficit and Hyperactivity Disorder (ADHD)patients.Data on Autism Spectrum Disorder (ASD)and AD patients in the same study are expected later this year.

"Our continued investment in Oryzonreflects ADDF's long-standing support of studies that focus on drugs targeted toward multiple aging pathways" says Howard Fillit, M.D., founding executive director and chief science officer of the ADDF. "We are pleased to help advancethe development of epigenetic therapies and vafidemstat as anovel therapeutic option for Alzheimer's disease."

Michael Ropacki, Oryzon’s Vice-President of Clinical Development, has stated:“We appreciate the generosity of the ADDF, and their support to furthervafidemstat’s clinical development. The unique mechanism of action along with safety and efficacy data collected to-date suggest that vafidemstat may positively impact cognition, as well as the neuropsychiatric sequelae and behavioral problems of AD patients.”

Carlos Buesa,CEO and Founder of Oryzon,said: “Support from the ADDF has been keyover the yearsto advancethe development of vafidemstat as anovel therapeutic option for Alzheimer’s disease, and we aredeeplygrateful. The ADDF’s decision to convert the grant into equity reflects its confidence in our project and theshared hope that this experimental drug may contribute to the cure of this terrible disease.With ETHERAL-US, the company is starting clinical operations in the US and we expect to expand the clinical trials with vafidemstat in the US to additional CNS indicationssoon”.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field.Oryzon’s LSD1 program has rendered two compounds vafidemstat and iadademstat in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases.Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com

About Vafidemstat

Vafidemstat (ORY-2001) is an oral, brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule acts on several levels: it reduces cognitive impairment, includingmemory loss and neuroinflammation, and at the same time has neuroprotective effects.In animal studiesvafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer’s disease, to normal levels and also reduces social avoidance and enhancessociabilityin murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Vafidemstat is inPhase IIa clinical studies in patients with Relapse-Remitting and Secondary Progressive MS (SATEEN),in patients with Mild to Moderate Alzheimer’s disease (ETHERAL)and in aggressiveness in patients with different psychiatric or neurodegenerative disorders (REIMAGINE, a basket trial).

About the Alzheimer's Drug Discovery

FoundationFounded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focusedon funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded over$115 millionto fund more than 590 Alzheimer's drug discovery programs and clinical trials in 18 countries. To learn more, please visit:http://www.alzdiscovery.org/.

US Contact: Solebury Trout - Thomas Hoffmann

Spain: ATREVIA Patricia Cobo/Idoia Revuelta

Oryzon: Emili Torrell - BD Director